Jan Starý
About
Jan Starý is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Molecular Biology.
According to data from OpenAlex, Jan Starý has authored 255 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 154 papers in Hematology, 125 papers in Public Health, Environmental and Occupational Health and 51 papers in Molecular Biology. Recurrent topics in Jan Starý's work include Acute Lymphoblastic Leukemia research (122 papers), Acute Myeloid Leukemia Research (102 papers) and Chronic Myeloid Leukemia Treatments (46 papers). Jan Starý is often cited by papers focused on Acute Lymphoblastic Leukemia research (122 papers), Acute Myeloid Leukemia Research (102 papers) and Chronic Myeloid Leukemia Treatments (46 papers). Jan Starý collaborates with scholars based in Czechia, Germany and Netherlands. Jan Starý's co-authors include Dirk Reinhardt, Jan Trka, Ursula Creutzig, Michael Dworzak, Martin Zimmermann, Jan Zuna, Ondřej Hrušák, Thomas Lehrnbecher, Martin Schrappe and Petr Sedláček and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
In The Last Decade
Jan Starý
245 papers receiving 4.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jan Starý Czechia | 42 | 3.1k | 2.4k | 1.5k | 1.0k | 931 | 255 | 5.0k | ||
| Michael Dworzak Austria | 45 | 3.6k 1.2× | 3.0k 1.2× | 1.2k 0.8× | 1.2k 1.2× | 1.0k 1.1× | 189 | 5.8k | ||
| Elisabeth R. van Wering Netherlands | 40 | 2.4k 0.8× | 3.1k 1.3× | 1.4k 0.9× | 653 0.6× | 1.3k 1.4× | 101 | 4.6k | ||
| Patrick A. Brown United States | 38 | 2.8k 0.9× | 1.7k 0.7× | 2.9k 1.9× | 1.3k 1.3× | 758 0.8× | 160 | 5.7k | ||
| Erik Forestier Sweden | 36 | 2.3k 0.7× | 2.9k 1.2× | 1.0k 0.7× | 745 0.7× | 1.5k 1.6× | 109 | 4.2k | ||
| Georg Mann Austria | 39 | 2.2k 0.7× | 2.6k 1.1× | 781 0.5× | 1.0k 1.0× | 1.2k 1.3× | 147 | 4.5k | ||
| Nicolas Boissel France | 42 | 3.6k 1.2× | 1.9k 0.8× | 2.0k 1.4× | 1.5k 1.4× | 466 0.5× | 200 | 6.1k | ||
| André Schrauder Germany | 31 | 1.9k 0.6× | 2.1k 0.9× | 562 0.4× | 770 0.7× | 929 1.0× | 77 | 3.3k | ||
| Vinod Pullarkat United States | 38 | 3.8k 1.2× | 1.3k 0.5× | 1.9k 1.3× | 1.2k 1.1× | 448 0.5× | 228 | 6.0k | ||
| CH Pui United States | 32 | 2.0k 0.6× | 2.5k 1.0× | 952 0.6× | 613 0.6× | 697 0.7× | 64 | 3.8k | ||
| W M Crist United States | 41 | 1.9k 0.6× | 2.3k 0.9× | 1.4k 1.0× | 2.0k 2.0× | 970 1.0× | 75 | 6.1k |
Countries citing papers authored by Jan Starý
Since
Specialization
Citations
This map shows the geographic impact of Jan Starý's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Starý with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Starý more than expected).
Fields of papers citing papers by Jan Starý
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jan Starý. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Starý. The network helps show where Jan Starý may publish in the future.
Co-authorship network of co-authors of Jan Starý
This figure shows the co-authorship network connecting the top 25 collaborators of Jan Starý. A scholar is included among the top collaborators of Jan Starý based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Starý. Jan Starý is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Svatoň, Michael, Petr Sedláček, Renata Formánková, et al.. (2025). NGS‐MRD negativity in post‐HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk. HemaSphere. 9(4). e70124–e70124.
2.
Nováková, Michaela, Markéta Žaliová, Eva Froňková, et al.. (2022). CD38: A target in relapsed/refractory acute lymphoblastic leukemia—Limitations in treatment and diagnostics. Pediatric Blood & Cancer. 69(9). e29779–e29779.
3.
Lehrnbecher, Thomas, Andreas H. Groll, Simone Cesaro, et al.. (2022). Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009. Leukemia. 37(1). 72–78.
4.
Würthwein, Gudrun, Claudia Lanvers‐Kaminsky, Joachim Gerß, et al.. (2021). Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data. European Journal of Drug Metabolism and Pharmacokinetics. 46(2). 289–300.
5.
Rasche, Mareike, Martin Zimmermann, Jean‐Pierre Bourquin, et al.. (2021). Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group. Cancers. 13(4). 789–789.
6.
Štěrba, Jaroslav, et al.. (2021). Development of the Czech Childhood Cancer Information System: Data Analysis and Interactive Visualization. JMIR Public Health and Surveillance. 7(6). e23990–e23990.
7.
Potůčková, Eliška, Lucie Šrámková, Jan Starý, et al.. (2018). Two novel fusion genes, AIF1L‐ETV6 and ABL1‐AIF1L, result together with ETV6‐ABL1 from a single chromosomal rearrangement in acute lymphoblastic leukemia with prenatal origin. Genes Chromosomes and Cancer. 57(9). 471–477.
8.
Šrámková, Lucie, et al.. (2016). Lethargic infant: severe deficiency of vitamin B12. Pediatrie pro praxi. 17(3). 173–176.
9.
Švojgr, Karel, David Sumerauer, Alena Puchmajerová, et al.. (2015). Fanconi anemia with biallelic FANCD1/BRCA2 mutations – Case report of a family with three affected children. European Journal of Medical Genetics. 59(3). 152–157.
10.
Yoshimi, Ayami, Irith Baumann, Marek Ussowicz, et al.. (2015). Long-term results of the 'Prospective study of the diagnosis and treatment of myelodysplastic syndromes in childhood (EWOG-MDS98)'. Haematologica. 100. 1–1.
11.
Vašková, Martina, Ester Mejstříková, Tomáš Kalina, et al.. (2014). Cytokines, growth, and environment factors in bone marrow plasma of acute lymphoblastic leukemia pediatric patients. European Cytokine Network. 25(1). 8–13.
12.
Creutzig, Ursula, Martin Zimmermann, Jean‐Pierre Bourquin, et al.. (2013). Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood. 122(1). 37–43.
13.
Creutzig, Ursula, Martin Zimmermann, Jean‐Pierre Bourquin, et al.. (2011). CNS irradiation in pediatric acute myleoid leukemia: Equal results by 12 or 18 Gy in studies AML‐BFM98 and 2004. Pediatric Blood & Cancer. 57(6). 986–992.
14.
Balgobind, Brian V., Iris H.I.M. Hollink, Susan T.C.J.M. Arentsen-Peters, et al.. (2011). Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica. 96(10). 1478–1487.
15.
Baumann, In go, Monika Führer, Barbara De Moerloose, et al.. (2011). Immunosuppressive therapy with anti-thymocyte globin and cyclosporine A in patients with refractory cytopenia in childhood. Bone Marrow Transplantation. 46.
16.
Zimmermann, Martin, Manuela Germeshausen, Nils von Neuhoff, et al.. (2010). Granulocyte Colony-Stimulating Factor (G-CSF) Treatment of Childhood Acute Myeloid Leukemias That Overexpress the Differentiation-Defective G-CSF Receptor Isoform IV Is Associated With a Higher Incidence of Relapse. Journal of Clinical Oncology. 28(15). 2591–2597.
17.
Mejstříková, Ester, Eva Froňková, Tomáš Kalina, et al.. (2010). Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria. Haematologica. 95(6). 928–935.
18.
Čmejla, Radek, Jana Čmejlová, Jir̆ı́ Petrák, et al.. (2009). Identification of mutations in the ribosomal protein L5 (RPL5) and ribosomal protein L11 (RPL11) genes in Czech patients with Diamond-Blackfan anemia. Human Mutation. 30(3). 321–327.
19.
Kobylka, Petr, Zdeňka Gašová, Iuri Marinov, et al.. (2001). Comparison of two different methods for CD34+ selection and T cell depletion in peripheral blood stem cell grafts--our experiences with CellPro, E rosetting and CliniMACS technique.. PubMed. 48(5). 374–81.
20.
Trka, Jan, Jan Zuna, C Haškovec, et al.. (1999). [Detection of BCR/ABL, MLL/AF4 and TEL/AML1 hybrid genes and monitoring of minimal residual disease in pediatric patients with acute lymphoblastic leukemia].. PubMed. 138(1). 12–7.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Michael Dworzak Breakdown of academic impact, for papers by Elisabeth R. van Wering Breakdown of academic impact, for papers by Patrick A. Brown Breakdown of academic impact, for papers by Erik Forestier Breakdown of academic impact, for papers by Georg Mann Breakdown of academic impact, for papers by Nicolas Boissel Breakdown of academic impact, for papers by André Schrauder Breakdown of academic impact, for papers by Vinod Pullarkat Breakdown of academic impact, for papers by CH Pui Breakdown of academic impact, for papers by W M Crist